gsk rsv news - Search News

Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US

Analysis-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.

YAHOO!Finance · 4h

GSK reports positive findings from Phase III RSV vaccine trial

The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.

Seeking Alpha · 2d

U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report

Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.

Hosted on MSN · 2d

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,

YAHOO!Finance · 23h

GSK says RSV vaccine protects against disease over three seasons

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK RSV shot 43% effective against severe disease in third year

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

McKnight's Long-Term Care News15h

RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

kffhealthnews3h

GSK’s Widely Used RSV Shot Retains 43% Potency In Third Year, Data Show

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

FiercePharma1d

GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

ENDPOINTS NEWS20h

GSK's RSV vaccine Arexvy shows long-term protection in Phase 3 trial

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The Pharma Letter5h

GSK hopes for Arexvy boost after positive Phase III data

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

Pharmabiz7h

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

Low RSV and COVID vaccine usage is in line with investor expectations, but concerning: Jefferies

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst said, and could mean weak earnings for ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results